RxDoctor Payments Data

Mohsin Hamid, MD

Internal Medicine · Abington, PANPI 1134501539

Payments from drug & device makers

$10,146in general payments, 2019–2025

Across 246 payments — averaging $41.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Intuitive Surgical$5K
  • AstraZeneca$1K
  • Actelion Pharmaceuticals US, Inc.$912
  • GSK$792
  • Regeneron Healthcare Solutions, Inc.$577
  • Boehringer Ingelheim$318
  • plus $1K from 17 others

What the payments were for

  • Travel & lodging$2,50225%
  • Food & beverage$4,97949%
  • Education$2,66426%

General payments by program year

19
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$10,146 in reported general payments places this provider in the 90th percentile of 5,705 internal medicine providers in Pennsylvania.

See all internal medicine providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$71,451
Medicare patients
217
Services billed
541

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Dupixent PenDupilumab67$243,995
Trelegy ElliptaFluticasone/Umeclidin/Vilanter216$162,129
NucalaMepolizumab12$107,959
TezspireTezepelumab-Ekko12$55,916
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr34$18,216
Breztri AerosphereBudesonide/Glycopyr/Formoterol15$12,644
Stiolto RespimatTiotropium Br/Olodaterol Hcl18$11,600
Tiotropium Bromide15$6,726
Roflumilast37$4,338
Albuterol Sulfate HfaAlbuterol Sulfate62$2,337
Ventolin HfaAlbuterol Sulfate32$1,708
Azelastine Hcl75$1,440
Fluticasone Propionate54$682
Montelukast Sodium42$434
Pantoprazole Sodium13$230

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Nucala, Anoro Ellipta$792$288,304262 claims
AstraZenecaTezspire, Breztri Aerosphere$1,301$68,56027 claims
Boehringer IngelheimStiolto Respimat$318$11,60018 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 5,705 internal medicine providers in Pennsylvania.

Other internal medicine in Abington

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →